BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients

BeiGene Ltd BGNE announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to bendamustine and rituximab (B+R).
The trial included patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p]).
With a median follow-up of 25.8 months, Brukinsa achieved a highly statistically significant improvement in progression-free survival (PFS) compared to B+R, as assessed by an independent review committee, the trial's primary endpoint.
In addition, the trial demonstrated a statistically significant improvement in PFS per investigator assessment, a secondary endpoint.
Brukinsa was also generally well-tolerated, consistent with its known safety profile.
Price Action: BGNE shares closed at $312.19 on Thursday.